Refine by
Cancer Cell Technology
30 companies found
Technologybased inFoothill Ranch, CALIFORNIA (USA)
TAE Life Sciences (TLS) is a biologically-targeted radiation therapy company focused on developing novel treatments to improve the lives of patients with invasive, recurrent and difficult to treat cancers. Founded in 2017, TLS is the only company ...
Gordon Locher first proposed Boron Neutron Capture Therapy (BNCT) in 1936. Clinical investigation and treatments were first introduced in the USA in the 1950s and showed promising results. Historically, BNCT clinical studies have been carried out ...
Technologybased inHamburg, GERMANY
Revvity Gene Delivery (formerly SIRION Biotech) supports your cell and gene therapy development process ̶ offering solutions for early R&D all the way to clinical applications, with easy transfer of processes and assays into GMP production. ...
Technologybased inCarlton South, AUSTRALIA
Chimeric Therapeutics is a clinical stage cell therapy company focused on bringing the promise of cell therapy to life for more patients with cancer. We believe that cellular therapies have the promise to cure cancer not just delay disease ...
Cell therapy is the transfer of intact, live cells into a patient to help lessen or cure a disease. The most common and simple type of cell therapy is a blood transfusion. Other commonly known cell therapies include red and white blood cell ...
Technologybased inVancouver, BRITISH COLUMBIA (CANADA)
Zymeworks Inc. is a publicly listed (NYSE: ZYME), clinical-stage, biopharmaceutical company dedicated to the discovery, development, and commercialization of next-generation multifunctional biotherapeutics, initially focused on the treatment of ...
in a single, transferable, conditionally active design. Right Place at the Right Time. With PROgrammed Tumor Engagement & Checkpoint/Co-stimulation Targeting, the ProTECT platform delivers multifunctional tumor-specific activity while ...
Technologybased inHørsholm, DENMARK
We are an AI-immunology platform company decoding the human immune system to discover and develop novel immunotherapies for cancer and infectious diseases. We have developed our AI-immunology core technology to deeply understand the biological ...
PIONEER is our proprietary AI platform for the rapid discovery and design of patient-specific neoepitopes used to derive immuno-oncology therapies. It has been shown that neoepitopes, which arise from patient-specific tumor mutations, play a ...
Technologybased inSTONY BROOK, NEW YORK (USA)
Alpha-1 Biologics was founded by Cynthia L. Bristow, PhD, in June, 2011 for the purpose of developing patented biotechnology related to the generation of immune cells from stem cells within the body to treat immunodeficiency with the following ...
Technologybased inBundoora, AUSTRALIA
AdAlta is an innovative, clinical stage biotech company developing a unique range of new drug treatments. AdAlta has pioneered a technology that mimics the shape and stability of a crucial antigen-binding domain, discovered initially in sharks and ...
AdAlta and Carina Biotech to develop next-generation i-body enabled CAR-T cancer therapeutics. AdAlta has entered a collaboration agreement with Carina Biotech to develop next-generation i-body enabled CAR-T cells, ...
Technologybased inCambridge, MASSACHUSETTS (USA)
We are a cell therapy company that combines a novel patient engineering approach with targeted therapies to provide a solution for patients suffering from hematological malignancies. Vor, the Norse goddess of wisdom, was known as the careful one. ...
The traditional tumor target paradigm aims to treat hematological malignancies such as acute myeloid leukemia (AML) by focusing on the specificity and potency of therapies that kill cancer cells expressing a target. ...
Technologybased inSchlieren, SWITZERLAND
We want to empower people to deal with their malignant cells through their own immune system just like we deal with viral infections. Today’s cancer immunotherapies are powerful but, to the detriment of their effect, not very tumor-selective. ...
CDR-Life’s T cell engaging antibodies are potentially transformative in the field of cancer immunotherapies» Prof. Markus G. Manz, MD, Head of Medical Oncology and Hematology at University Hospital and ...
Technologybased inCambridge, UNITED KINGDOM
Based in Cambridge, one of Europe's largest bioscience hubs, Biorbyt has a simple yet challenging mission: to provide the best service to the global scientific community. We achieve this by collaborating with the world’s finest researchers and ...
Monoclonal antibodies; one of the most widely used tools in biological research, with the potential soon to become important therapeutics, have been with us for just over 40 years. These antibodies are monovalent, bind to a single epitope and are ...
Technologybased inSouth San Francisco, CALIFORNIA (USA)
Sutro Biopharma is a clinical stage company pioneering a compelling and unique way of discovering, developing and manufacturing therapeutics. Our focus is aimed primarily on next-generation cancer therapeutics – antibody drug conjugates, bispecific ...
Sutro’s cell-free expression technology provides a rapid and powerful platform for the discovery and development of next generation antibody-drug conjugates ...
Technologybased inSalt Lake City, UTAH (USA)
3Helix develops and markets a novel collagen targeting technology, providing scientists and clinicians with new tools to investigate collagen pathology and to develop diagnostics and therapeutics for diseases with high collagen remodeling ...
The collagen hybridizing peptide (CHP) is a novel and unique peptide that specifically binds unfolded collagen chains, both in vitro and in vivo.[1,2,3] By sharing the Gly-X-Y repeating sequence of natural collagen, CHP has a strong capability to ...
Technologybased inTehran, IRAN
Pars Isotope Co is a prominent supplier and producer of radioisotopes in Iran, catering widely to the medical and industrial sectors. As the sole provider in the region, the company focuses on radiopharmaceuticals used for both the diagnosis and ...
The PARS-LUTOTATE theranostic radiopharmaceutical kit is an innovative solution formulated as a single vial for the effective treatment of neuroendocrine tumors. It utilizes the Lu-177 radioisotope, enabling the radiopharmaceutical to selectively ...
Technologybased inBerkeley, CALIFORNIA (USA)
Caribou is a clinical-stage biopharmaceutical company, founded by pioneers in CRISPR genome editing, leveraging our proprietary technology to develop genome-edited off-the-shelf immune cell therapies for the treatment of cancer. We believe that cell ...
Natural killer (NK) cells, as their name implies, play an important role in ridding the body of cancer and viruses. NK cells are emerging as an increasingly important cell type ...
Technologybased inToronto, ONTARIO (CANADA)
Theralase was one of the first companies in North America to bring CLT to patients and the first company in the world to bring personalized ACT to patients individual tissue characteristics. With our multi-discipline experience in physics, ...
Theralase is laser focused on advancing the cutting-edge Anti-Cancer Therapy (“ACT”) towards commercialization, providing an alternative treatment methodology for Non-Muscle Invasive Bladder Cancer (“NMIBC”) patients ...
Technologybased inSeoul, SOUTH KOREA
GI Innovation is a bio-venture company that researches and develops innovative protein new drugs through well-structured translational research. The primary research and development for GI Innovation is immuno-oncology drug and allergy disease and ...
Promotes the generation of cancer-specific effector T cell (Teff) in lymph nodes, and induces the activation and proliferation of tumor-infiltrating Teff and NK cells. Controls the ...
Technologybased inAustin, TEXAS (USA)
Natera is a global leader in cell-free DNA (cfDNA) testing, dedicated to oncology, women’s health, and organ health. We aim to make personalized genetic testing and diagnostics part of the standard of care to protect health and inform earlier, more ...
Signatera is a personalized, tumor-informed assay optimized to detect circulating tumor DNA (ctDNA) for molecular residual disease (MRD) assessment and recurrence monitoring for patients previously diagnosed with cancer, with broad utility for ...
Technologybased inFriendswood, TEXAS (USA)
Castle Biosciences (Nasdaq: CSTL) is a leading diagnostics company improving health through innovative tests that guide patient care. The Company aims to transform disease management by keeping people first: patients, clinicians, employees and ...
Predicting Individual Risk of Recurrence or Metastasis: DecisionDx-Melanoma was designed to address the need for a more accurate predictor of metastatic risk in patients diagnosed with cutaneous (skin) melanoma. ...
Technologybased inNew York, NEW YORK (USA)
Stemline Therapeutics is a commercial-stage biopharmaceutical company focused on the development and commercialization of novel oncology therapeutics. The goal of our dedicated team of scientists, specialists, researchers, and developers is to build ...
CD123 is expressed on multiple malignancies including BPDCN, AML, certain myeloproliferative neoplasms (MPNs), myelodysplastic syndrome (MDS), chronic myeloid leukemia (CML), B-cell acute lymphoid leukemia (B-ALL), hairy ...
Technologybased inEdinburgh, UNITED KINGDOM
Edinburgh Molecular Imaging is a clinical phase biotechnology company focused on enabling image guided interventional medicine. The company´s molecular targetting technology has the potential to tackle disease in real-time to allow interventional ...
